Treatment of community-associated methicillin-resistant Staphylococcus aureus

被引：7
作者：
Popovich K.J. [1 ]
Hota B. [1 ]
Weinstein R.A. [1 ]
机构：
[1] Chicago, IL 60612
来源：
Current Infectious Disease Reports | 2007年 / 9卷 / 5期
关键词：
Linezolid; Daptomycin; Necrotizing Fasciitis; Mupirocin; Nasal Carriage;
D O I：
10.1007/s11908-007-0062-8
中图分类号：
学科分类号：
摘要：
Methicillin-resistant Staphylococcus aureus has emerged in the community among patient populations without traditional antibiotic resistance risk factors and is causing a variety of clinical syndromes, in particular skin and soft tissue infections. These infections can range from minor skin involvement that can be treated in an outpatient setting to more serious infections such as necrotizing fasciitis requiring hospitalization. Inpatient and outpatient healthcare providers must be aware of the treatment, prevention, and infection control practices for this emerging pathogen. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：398 / 407
页数：9
相关论文
共 81 条
[1]  
Fridkin S.K., Hageman J.C., Morrison M., Et al., Methicillin-resistant Staphylococcus aureus disease in three communities, N Engl J Med, 352, pp. 1436-1444, (2005)
[2]  
Miller L.G., Perdreau-Remington F., Bayer A.S., Et al., Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: A prospective investigation, Clin Infect Dis, 44, pp. 471-482, (2007)
[3]  
Vandenesch F., Naimi T., Enright M.C., Et al., Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence, Emerg Infect Dis, 9, pp. 978-984, (2003)
[4]  
Witte W., Cuny C., Strommenger B., Et al., Emergence of a new community acquired MRSA strain in Germany, Euro Surveill, 9, pp. 16-18, (2004)
[5]  
Larsen A., Stegger M., Goering R., Et al., Emergence and dissemination of the methicillin resistant Staphylococcus aureus USA300 clone in Denmark (2000-2005), Euro Surveill, 12, (2007)
[6]  
Kluytmans J., van Belkum A., Verbrugh H., Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks, Clin Microbiol Rev, 10, pp. 505-520, (1997)
[7]  
von Eiff C., Becker K., Machka K., Et al., Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group, N Engl J Med, 344, pp. 11-16, (2001)
[8]  
Kuehnert M.J., Kruszon-Moran D., Hill H.A., Et al., Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002, J Infect Dis, 193, pp. 172-179, (2006)
[9]  
Harbarth S., Liassine N., Dharan S., Et al., Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus, Clin Infect Dis, 31, pp. 1380-1385, (2000)
[10]  
Harbarth S., Dharan S., Liassine N., Et al., Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 43, pp. 1412-1416, (1999)
123456789